Shareholders are entitled to have a matter addressed by the Annual General Meeting as long as their request has been received by the Board of Directors by 27 February 2015. The Board of Directors can be contacted by email at: email@example.com, or by mail at: NeuroVive Pharmaceutical AB, FAO: Greg Batcheller, Medicon Village, 223 81 Lund, Sweden.
The AGM on 9 May 2014 resolved that NeuroVive shall have a Nomination Committee comprising one member of each of the three largest shareholders in terms of voting rights based on ownership statistics maintained by Euroclear Sweden AB as of 30 June 2014. If a shareholder does not exercise its right to appoint a member, entitlement to appoint a member of the Nomination Committee shall transfer to that member who is the second largest shareholder in terms of voting rights. The Nomination Committee’s period of office runs until a new Nomination Committee has been appointed.
The Nomination Committee ahead of the AGM 2015 comprises:
- Michael Vickers (Chairman of the Nomination Committee) appointed by Maas Biolab LLC,
- Anders Ermén appointed by Baulus Capital Belgium SA, and
- Tomas Hagström appointed by Eskil Elmér.
In total, the Nomination Committee represents some 30% of the votes in NeuroVive as of 30 September 2014.
The Nomination Committee’s task ahead of the AGM 2015 is to prepare proposals on the following matters to present to the AGM for resolution:
- Propose the Chairman of the AGM,
- Propose the number of Board members and, where applicable, the number of Auditors,
- Propose remuneration to Board members and remuneration to Committee members,
- Propose remuneration to the Auditors,
- Propose the Chairman of the Board and other Board members and, where applicable, Auditors,
- Propose guidelines for appointing members of the Nomination Committee and the assignments of the Nomination Committee,
- Propose remuneration to the members of the Nomination Committee.
Shareholders wishing to propose members of the Nomination Committee can contact the Committee by email at: firstname.lastname@example.org, or by mail at: NeuroVive Pharmaceutical AB, FAO: Nomination Committee, Medicon Village, 223 81 Lund, Sweden. In order for the Nomination Committee to consider the proposals received with due care, proposals must be received by the Nomination Committee by no later than 16 February 2015.
About NeuroVive Pharmaceutical
NeuroVive Pharmaceutical AB (publ), a leading mitochondrial medicine company, is developing a portfolio of products to treat acute cardiovascular and neurological conditions through mitochondrial protection. These medical conditions are characterized by a pressing medical need and have no approved pharmaceutical treatment options at present. NeuroVive’s products CicloMulsion® (heart attack) and NeuroSTAT® (traumatic brain injury) are currently being evaluated in phase III and phase II studies, respectively. NeuroVive’s research programs also include products for the treatment of antiviral indications (Hepatitis B/C), brain cell injury in stroke patients, and drug candidates for cellular protection and treating mitochondria-related energy regulation diseases. NeuroVive’s shares are listed on NASDAQ OMX, Stockholm, Sweden.
For Investor Relations and media questions, please contact:
Ingmar Rentzhog, Laika Consulting, Tel: +46 (0)46 275 62 21 or email@example.com
It is also possible to arrange an interview with NeuroVive’s CEO Mikael Brönnegård at the above contact.
NeuroVive Pharmaceutical AB (publ)
Medicon Village, SE-223 81 Lund, Sweden
Tel: +46 (0)46 275 62 20 (switchboard), Fax: +46 (0)46 888 83 48
NeuroVive Pharmaceutical AB (publ) is required to publish the information in this news release under The Swedish Securities Market Act. The information was submitted for publication on 29 October 2014, at 8.30 a.m. CET.